ES2565063T3 - Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 - Google Patents

Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 Download PDF

Info

Publication number
ES2565063T3
ES2565063T3 ES12715856.6T ES12715856T ES2565063T3 ES 2565063 T3 ES2565063 T3 ES 2565063T3 ES 12715856 T ES12715856 T ES 12715856T ES 2565063 T3 ES2565063 T3 ES 2565063T3
Authority
ES
Spain
Prior art keywords
cancer
cell
carcinoma
tumor
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12715856.6T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Korden Walter
Stefan WÖLL
Maria Kreuzberg
Bernd Hubner
Michael Erdeljan
Michael WEICHEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg Universitaet Mainz
Ganymed Pharmaceuticals GmbH
Original Assignee
Johannes Gutenberg Universitaet Mainz
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47176322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2565063(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johannes Gutenberg Universitaet Mainz, Ganymed Pharmaceuticals GmbH filed Critical Johannes Gutenberg Universitaet Mainz
Application granted granted Critical
Publication of ES2565063T3 publication Critical patent/ES2565063T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Anticuerpo que comprende: (i) una cadena pesada de anticuerpo que comprende una secuencia de cadena pesada de anticuerpo de SEC ID nº 36, y (ii) una cadena ligera de anticuerpo que comprende una secuencia de cadena ligera de anticuerpo seleccionada de entre SEC ID nº 35, nº 54 y nº 55.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
5
15
25
35
45
55
65
de cáncer preferentemente son aquellas en las que las células tumorales o las células de cáncer expresan CLDN6 y se caracterizan por la asociación de CLDN6 con la superficie celular de las mismas.
Tal como se utiliza en la presente memoria, una "enfermedad tumoral", una "enfermedad de tipo tumoral" o una "enfermedad tumorigénica" se refiere a una enfermedad caracterizada por una multiplicación, proliferación, diferenciación, adhesión y/o migración celulares reguladas de manera aberrante, lo que puede resultar en la producción, o en la tendencia a producir, tumores y/o metástasis tumorales. La expresión "célula tumoral" se refiere a una célula anormal que se multiplica mediante una proliferación celular no controlada rápida y que continúa multiplicándose después de cesar los estímulos que iniciaron la nueva multiplicación.
El término "tumor" se refiere a un grupo anormal de células o a un tejido que crece mediante una proliferación celular no controlada rápida y que continúa creciendo tras cesar los estímulos que iniciaron el nuevo crecimiento. Los tumores muestran una falta parcial o total de organización estructural y coordinación funcional con el tejido normal, y habitualmente forman una masa diferenciada de tejido, que puede ser benigna, premaligna o maligna.
Preferentemente, una "enfermedad tumoral", "enfermedad de tipo tumoral" o "enfermedad tumorigénica" según la invención es una enfermedad de cáncer, es decir, una enfermedad maligna y una célula tumoral es una célula de cáncer. Preferentemente una "enfermedad tumoral", "enfermedad de tipo tumoral" o "enfermedad tumorigénica" se caracteriza por células que expresan CLDN6 y que se caracterizan por la asociación de CLDN6 con la superficie celular de las mismas y una célula tumoral expresa CLDN6 y se caracteriza por la asociación de CLDN6 con la superficie celular.
Una célula que expresa CLDN6 y que se caracteriza por la asociación de CLDN6 con la superficie celular preferentemente es una célula tumoral o una célula de cáncer, preferentemente de los tumores y cánceres indicados en la presente memoria. Preferentemente, dicha célula es una célula diferente de una célula placentaria.
Las enfermedades de cáncer preferentes o cánceres según la invención se seleccionan de entre el grupo que consiste de cáncer ovárico, en particular adenocarcinoma ovárico y teratocarcinoma ovárico, cáncer de pulmón, incluyendo el cáncer de pulmón microcítico (SCLC) y el cáncer de pulmón no microcítico (NSCLC), en particular el carcinoma y el adenocarcinoma pulmonares de células escamosas, cáncer gástrico, cáncer de mama, cáncer hepático, cáncer pancreático, cáncer de piel, en particular el carcinoma de células basales y el carcinoma de células escamosas, melanoma maligno, cáncer de cabeza y cuello, en particular el adenoma pleomórfico maligno, sarcoma, en particular el sarcoma y el carcinosarcoma sinoviales, cáncer de conductos biliares, cáncer de la vejiga urinaria, en particular el carcinoma de células transicionales y el carcinoma papilar, cáncer de riñón, en particular el carcinoma de células renales, incluyendo el carcinoma de células renales de células claras y el carcinoma de células renales papilar, cáncer de colon, cáncer de intestino delgado, incluyendo el cáncer del íleo, en particular el adenocarcinoma del intestino delgado y el adenocarcinoma del íleo, carcinoma embrionario testicular, coriocarcinoma placentario, cáncer cervical, cáncer testicular, en particular el seminoma testicular, teratoma testicular y cáncer testicular embrionario, cáncer uterino, un tumor de células germinativas tal como un teratocarcinoma o un carcinoma embrionario, en particular un tumor de células germinativas del testículo, y las formas metastásicas de los mismos.
Los tipos principales de cáncer de pulmón son el carcinoma de pulmón microcítico (SCLC) y el carcinoma de pulmón no microcítico (NSCLC). Existen tres subtipos principales de carcinoma de pulmón de células no pequeñas: el carcinoma de pulmón de células escamosas, el adenocarcinoma y el carcinoma de pulmón de células grandes. Los adenocarcinomas constituyen aproximadamente el 10% de los cánceres de pulmón. Este cáncer habitualmente se observa periféricamente en los pulmones, al contrario cáncer de pulmón microcítico (SCLC) y el cáncer de pulmón escamoso, los cuales tienden a localizarse más centralmente.
El cáncer de piel es un crecimiento maligno sobre la piel. Los cánceres de piel más comunes son el cáncer de células basales, el cáncer de células escamosas y el melanoma. El melanoma maligno es un tipo grave de cáncer de piel. Se debe a la multiplicación descontrolada de las células pigmentarias denominadas melanocitos.
Según la invención, un "carcinoma" es un cáncer que se inicia en la capa de revestimiento (células epiteliales) de los órganos.
El "carcinoma bronquiolar" es un carcinoma del pulmón que se cree que deriva del epitelio de los bronquiolos terminales, en los que el tejido neoplásico se extiende a lo largo de las paredes alveolares y crece en pequeñas masas dentro de los alveolos. Puede observarse mucina en algunas de las células y en el material en los alveolos, que también incluye células denudadas.
El "adenocarcinoma" es un cáncer que se origina en tejido glandular. Este tejido también es parte de una categoría más grande de tejidos conocida como tejido epitelial. El tejido epitelial incluye piel, glándulas y una diversidad de otros tejidos que revisten las cavidades y los órganos del cuerpo. El epitelio se deriva embriológicamente del ectodermo, endodermo y mesodermo. Para clasificarse como adenocarcinoma, las células no necesitan ser necesariamente una parte de una glándula, con la condición de que presenten propiedades secretorias. Esta forma de carcinoma puede producirse en algunos mamíferos superiores, incluyendo el ser humano. Los adenocarcinomas
22
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59

Claims (1)

  1. imagen1
    imagen2
ES12715856.6T 2011-05-13 2012-04-20 Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 Active ES2565063T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486071P 2011-05-13 2011-05-13
EP11004004 2011-05-13
EP11004004 2011-05-13
US201161486071P 2011-05-13
PCT/EP2012/001721 WO2012156018A1 (en) 2011-05-13 2012-04-20 Antibodies for treatment of cancer expressing claudin 6

Publications (1)

Publication Number Publication Date
ES2565063T3 true ES2565063T3 (es) 2016-03-31

Family

ID=47176322

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18179328T Active ES2989943T3 (es) 2011-05-13 2012-04-20 Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
ES12715856.6T Active ES2565063T3 (es) 2011-05-13 2012-04-20 Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18179328T Active ES2989943T3 (es) 2011-05-13 2012-04-20 Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6

Country Status (28)

Country Link
US (5) US9321842B2 (es)
EP (4) EP4464382A3 (es)
JP (3) JP6276176B2 (es)
KR (3) KR102072183B1 (es)
CN (3) CN107090043B (es)
AR (2) AR086306A1 (es)
AU (4) AU2012258087B2 (es)
BR (1) BR112013029212B1 (es)
CA (1) CA2832174C (es)
CY (2) CY1118608T1 (es)
DK (2) DK3026064T3 (es)
ES (2) ES2989943T3 (es)
HR (2) HRP20160212T1 (es)
HU (1) HUE028603T2 (es)
IL (1) IL228738B (es)
LT (1) LT3026064T (es)
ME (1) ME02369B (es)
MX (5) MX372766B (es)
NZ (2) NZ706004A (es)
PL (3) PL3026064T3 (es)
RS (2) RS58087B1 (es)
RU (1) RU2676731C2 (es)
SG (1) SG193551A1 (es)
SI (2) SI2707390T1 (es)
SM (1) SMT201600064B (es)
UA (2) UA127584C2 (es)
WO (1) WO2012156018A1 (es)
ZA (1) ZA201307102B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370554B1 (en) 2008-11-28 2019-05-15 Corbion Biotech, Inc. Manufacturing of tailored oils in recombinant heterotrophic microorganisms
ES2963717T3 (es) 2009-02-20 2024-04-01 Astellas Pharma Inc Métodos y composiciones para el diagnóstico y tratamiento del cáncer
RU2675997C2 (ru) * 2009-11-11 2018-12-25 Ганимед Фармасьютикалз Аг Антитела, специфичные к клаудину 6 (cldn6)
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
RS58087B1 (sr) 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3738612A1 (en) * 2013-07-31 2020-11-18 Biontech AG Diagnosis and therapy of cancer involving cancer stem cells
BR112016010169A2 (pt) * 2013-11-06 2017-12-05 Stemcentrx Inc anticorpos anticlaudina e métodos de uso
TWI652279B (zh) 2013-11-11 2019-03-01 中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
US10214584B2 (en) 2014-01-15 2019-02-26 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
SI3708579T1 (sl) * 2014-04-01 2024-09-30 Biontech Cell & Gene Therapies Gmbh Klavdin-6 specifični imunoreceptorji in T celični epitopi
EP4632120A3 (en) 2014-11-11 2026-01-07 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
CN105504051B (zh) * 2015-12-17 2019-08-30 北京天成新脉生物技术有限公司 狂犬病毒核蛋白单克隆抗体及其应用
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California CANCER TREATMENT COMBINATIONS
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
EP3562844A1 (en) * 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
SI3826667T1 (sl) * 2017-09-18 2024-09-30 The Regents Of The University Of California Protitelesa Claudin6 in metode zdravljenja raka
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
EP3735463A4 (en) * 2018-01-05 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
SG11202109986TA (en) * 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
PH12021552960A1 (en) 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
CN111087465B (zh) 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
JP6971419B2 (ja) 2020-03-31 2021-11-24 中外製薬株式会社 クローディン６を標的とする多重特異性抗原結合分子およびその使用
AU2021374036A1 (en) * 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
EP4301784A4 (en) * 2021-03-02 2025-01-01 NovaRock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
US12321428B2 (en) * 2021-07-08 2025-06-03 Nippon Telegraph And Telephone Corporation User authentication device, user authentication method, and user authentication computer program
JPWO2023053282A1 (es) 2021-09-29 2023-04-06
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
AU2022405694A1 (en) 2021-12-09 2024-07-04 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
CN120225555A (zh) * 2022-10-25 2025-06-27 恺兴生命科技(上海)有限公司 抗体及其应用
KR20250097820A (ko) 2022-10-31 2025-06-30 아스텔라스세이야쿠 가부시키가이샤 Toll양 수용체 7/8 듀얼 아고니스트 화합물을 포함하는 항체 약물 복합체
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
KR20250127134A (ko) 2022-12-29 2025-08-26 아스텔라스세이야쿠 가부시키가이샤 조작된 자연 살상 세포 및 관련 방법
CN116064622B (zh) * 2023-02-13 2023-10-13 优睿赛思(武汉)生物科技有限公司 Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用
WO2024184812A1 (en) * 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
WO2024235175A1 (zh) 2023-05-12 2024-11-21 智泽童康(广州)生物科技有限公司 抗cldn6抗体及其用途
CN121793985A (zh) 2023-05-25 2026-04-03 加利福尼亚大学校董会 治疗癌症的方法
CN120053694B (zh) * 2025-02-21 2025-10-03 中国农业大学 猪流行性腹泻抗病相关基因cldn4及其编码蛋白的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000035937A1 (en) 1998-12-17 2000-06-22 Human Genome Sciences, Inc. 47 human secreted proteins
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU773028B2 (en) 1998-11-03 2004-05-13 Adherex Technologies Inc. Compounds and methods for modulating claudin-mediated functions
AU3479700A (en) 1999-02-22 2000-09-14 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
DK1185648T3 (da) 1999-06-02 2007-07-30 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
EP1242443A4 (en) 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2006504630A (ja) * 2002-04-22 2006-02-09 ダイアックス コーポレイション ムチンポリペプチドに特異的な抗体
US20070207142A1 (en) 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
JP2006516192A (ja) 2002-10-18 2006-06-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
EP1633309A4 (en) 2003-05-30 2007-06-13 Centocor Inc METHOD FOR INHIBITING TUMOR GROWTH WITH ANTI-TISSUE FACTOR ANTIBODIES
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
DE102005025041A1 (de) 2005-05-30 2006-12-07 Bell Flavors & Fragrances Duft Und Aroma Gmbh Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CA2705164A1 (en) * 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
JP2011516580A (ja) 2008-04-11 2011-05-26 バイオノボ・インコーポレーテッド トウサイカチｇｌｅｄｉｔｓｉａｓｉｎｅｎｓｉｓｌａｍの抽出物を用いる抗癌方法
EA024492B1 (ru) * 2008-07-17 2016-09-30 Новартис Аг Антитела, специфически связывающиеся с baffr, и их применение
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
DE102009026960A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Verfahren zur Steuerung einer Bremsbetätigung eines Hybridfahrzeugs
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
ES2963717T3 (es) 2009-02-20 2024-04-01 Astellas Pharma Inc Métodos y composiciones para el diagnóstico y tratamiento del cáncer
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
RU2675997C2 (ru) 2009-11-11 2018-12-25 Ганимед Фармасьютикалз Аг Антитела, специфичные к клаудину 6 (cldn6)
WO2011105551A1 (ja) 2010-02-26 2011-09-01 国立大学法人大阪大学 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS58087B1 (sr) 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EP3388411A1 (en) 2017-04-13 2018-10-17 Sulzer Chemtech AG A process for purifying a crude composition including a monoterpene compound, such as a monocyclic monoterpene alcohol, by layer melt crystallization

Also Published As

Publication number Publication date
CN107090043B (zh) 2021-12-07
HRP20190014T1 (hr) 2019-02-22
NZ724296A (en) 2020-05-29
DK2707390T3 (en) 2016-02-29
SI3026064T1 (sl) 2019-03-29
EP3421496C0 (en) 2024-08-07
EP2707390B1 (en) 2015-12-30
AR086306A1 (es) 2013-12-04
RU2013155455A (ru) 2015-06-20
AU2012258087A1 (en) 2013-11-21
LT3026064T (lt) 2019-01-25
RS54627B1 (sr) 2016-08-31
HUE028603T2 (en) 2016-12-28
IL228738B (en) 2018-10-31
JP6276176B2 (ja) 2018-02-07
CY1121085T1 (el) 2019-12-11
HRP20160212T1 (hr) 2016-05-06
US20240101703A1 (en) 2024-03-28
PL2707390T3 (pl) 2016-06-30
DK3026064T3 (en) 2019-01-14
MX2020001224A (es) 2020-07-20
US20140127219A1 (en) 2014-05-08
PL3026064T3 (pl) 2019-05-31
NZ617214A (en) 2016-04-29
EP4464382A3 (en) 2025-03-05
CA2832174A1 (en) 2012-11-22
NZ741567A (en) 2023-10-27
AU2017204663A1 (en) 2017-07-27
ZA201307102B (en) 2016-08-31
KR102708094B1 (ko) 2024-09-24
EP4464382A2 (en) 2024-11-20
SI2707390T1 (sl) 2016-04-29
EP3421496A1 (en) 2019-01-02
US20210179730A1 (en) 2021-06-17
NZ706004A (en) 2016-12-23
WO2012156018A1 (en) 2012-11-22
MX372766B (es) 2020-06-29
EP2707390A1 (en) 2014-03-19
US10233253B2 (en) 2019-03-19
US10919974B2 (en) 2021-02-16
CN103748112A (zh) 2014-04-23
RU2676731C2 (ru) 2019-01-10
KR20220116069A (ko) 2022-08-19
US20190010244A1 (en) 2019-01-10
KR102430870B1 (ko) 2022-08-09
MX341147B (es) 2016-08-09
SMT201600064B (it) 2016-04-29
UA115969C2 (uk) 2018-01-25
UA127584C2 (uk) 2023-10-25
AR122771A2 (es) 2022-10-05
BR112013029212A2 (pt) 2016-11-29
CN103748112B (zh) 2017-02-15
RU2018145274A (ru) 2019-01-24
CN107090043A (zh) 2017-08-25
CY1118608T1 (el) 2017-07-12
US11859008B2 (en) 2024-01-02
EP3026064A1 (en) 2016-06-01
EP3026064B1 (en) 2018-10-17
MX2020011778A (es) 2020-11-24
KR20140033045A (ko) 2014-03-17
AU2021277764A1 (en) 2021-12-23
CN107011440B (zh) 2021-03-05
US20160264677A1 (en) 2016-09-15
AU2021277764B2 (en) 2025-03-13
RS58087B1 (sr) 2019-02-28
WO2012156018A8 (en) 2013-10-17
EP3421496B1 (en) 2024-08-07
JP6637083B2 (ja) 2020-01-29
HK1195320A1 (zh) 2014-11-07
AU2012258087B2 (en) 2017-07-20
KR102072183B1 (ko) 2020-02-03
JP2023089133A (ja) 2023-06-27
US9321842B2 (en) 2016-04-26
ME02369B (me) 2016-06-20
PL3421496T3 (pl) 2024-11-25
MX2013013053A (es) 2014-05-27
MX2020011779A (es) 2020-11-24
AU2017204663B2 (en) 2019-05-23
SG193551A1 (en) 2013-10-30
ES2989943T3 (es) 2024-11-28
JP2018095650A (ja) 2018-06-21
BR112013029212B1 (pt) 2020-05-19
IL228738A0 (en) 2013-12-31
AU2019219797A1 (en) 2019-09-12
CN107011440A (zh) 2017-08-04
AU2019219797B2 (en) 2021-09-09
JP2014516956A (ja) 2014-07-17
CA2832174C (en) 2024-02-27
KR20200078692A (ko) 2020-07-01
JP7636647B2 (ja) 2025-02-27

Similar Documents

Publication Publication Date Title
AR086306A1 (es) Anticuerpos para el tratamiento del cancer
Wee et al. Role of tumor-derived exosomes in cancer metastasis
Spano et al. Molecular networks that regulate cancer metastasis
Barati et al. Pluripotent stem cells: cancer study, therapy, and vaccination
US12247224B2 (en) Organoids for drug screening and personalized medicine
Fisher Myofibroblastic malignancies
Klöppel et al. Precancerous lesions of the biliary tree
Mohamet et al. Loss of function of e‐cadherin in embryonic stem cells and the relevance to models of tumorigenesis
CO2017002378A2 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
Benton et al. Laminin‐1 induces E‐cadherin expression in 3‐dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status
Câmara et al. Advances and challenges on cancer cells reprogramming using induced pluripotent stem cells technologies
Czerwińska et al. Application of induced pluripotency in cancer studies
MX2020004431A (es) Anticuerpos y metodos de uso.
Misdraji Tumours of the appendix
Van Phuc et al. Isolation and characterization of breast cancer stem cells from malignant tumours in Vietnamese women
Wang et al. Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer
Maffezzini et al. Bladder cancer
Altundag Breast cancer subtypes and local recurrence rate after surgery for bone metastasis to the extremities
Moriya et al. Malignant peripheral nerve sheath tumour arising from solitary sclerotic neurofibroma
Schoenborn Characterization of Tumor Suppressor PKP1 in Neoplastic Progression of Barrett
Sabol Next generation sequencing of small RNA in head and neck cancer
Joglekar et al. Metastatic primary cutaneous basaloid squamous cell carcinoma: transformation after 20 years of neglect.
Wijaya et al. Reversing breast cancer stem cell into breast somatic stem cell
Wroński et al. Parenchyma-Sparing Pancreatic Resections: With or Without a Pancreaticojejunostomy?
Serramia Cistoadenoma papilar de epidídimo